An approach to evaluating drug-nutrient interactions

Pharmacotherapy

Volumn 25, Issue 12 I, 2005, Pages 1789-1800

  Santos, Cristina A ^a   Boullata, Joseph I ^a,b  

^a TEMPLE UNIVERSITY   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

Drug evaluation process; Drug regimens; Drug nutrient interactions; Nutritional status

Indexed keywords

ALCOHOL; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; APREPITANT; BORTEZOMIB; CAFFEINE; CALCIUM; CYTOCHROME P450; DAPTOMYCIN; DIURETIC AGENT; EMTRICITABINE; GEFITINIB; GEMIFLOXACIN; ISONIAZID; ITRACONAZOLE; MAGNESIUM SULFATE; MONOAMINE OXIDASE INHIBITOR; MULTIVITAMIN; NEUROKININ 1 RECEPTOR; PALONOSETRON; PHENOBARBITAL; POTASSIUM CHLORIDE; PYRIDOXINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TETRACYCLINE; TYRAMINE; VITAMIN K GROUP; WARFARIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACUTE PANCREATITIS; ANOREXIA; ARTHRALGIA; ASTHENIA; BLOATING; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG DOSE REGIMEN; DYSESTHESIA; DYSGEUSIA; EDEMA; FOOD DRUG INTERACTION; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; GRAPEFRUIT; HEPATOMEGALY; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; INTESTINE OBSTRUCTION; META ANALYSIS; NAUSEA; NUTRIENT; NUTRITIONAL STATUS; PARESTHESIA; PATIENT CARE; PERIPHERAL NEUROPATHY; PNEUMONIA; RISK FACTOR; SENSORY NEUROPATHY; SHORT SURVEY; SKIN TOXICITY; STEATOSIS; SYSTEMATIC REVIEW; VOMITING; WEIGHT GAIN;

DIETARY SUPPLEMENTS; DRUG EVALUATION; FOOD-DRUG INTERACTIONS; HUMANS; INTESTINAL ABSORPTION; NUTRITIONAL STATUS; PHARMACEUTICAL SERVICES; PHARMACOKINETICS;

EID: 29044446719     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.12.1789     Document Type: Short Survey

References (89)

1. Boullata JI, Barber JR. A perspective on drug-nutrient interactions. In: Boullata JI, Armenti VA, eds. Handbook of drug-nutrient interactions. Totowa, NJ: Humana Press, 2004:3-25.
2. Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002;287:337-44.
3. Couris RR, Tataronis GR, Dallal GE, et al. Assessment of healthcare professionals' knowledge about warfarin-vitamin K drug-nutrient interactions. J Am Coll Nutr 2000;19:439-45.
4. Teresi ME, Morgan DE. Attitudes of healthcare professionals toward patient counseling on drug-nutrient interactions. Ann Pharmacother 1994;28:576-80.
5. Anonymous. Nutrition interventions manual for professionals caring for older Americans. Washington, DC: Nutrition Screening Initiative, 1992.
6. Binkley JF. Drug-nutrient interactions: we are required to look for them! Nutr Clin Pract 1998;13:199-200.
7. Pronsky ZM, Redfern CM, Crowe JP, Epstein S, eds. Food-medication interactions, 13th ed. Birchrunville, PA: Food Medication Interactions, 2003.
8. Harkness R, Bratman S. Handbook of drug-herb and drug-supplement interactions. St. Louis, MO: Mosby, 2003.
9. Roe DA. Handbook on drug and nutrient interactions: a reference and study guide, 5th ed. Chicago IL: American Dietetic Association, 1994.
10. Merck & Co., Inc. Emend (aprepitant) capsules prescribing information. Whitehouse Station, NJ; 2003. Available from http://www.fda.gov/ cder/foi/label/2004/21549s007lbl.pdf. Accessed January 10, 2005.
11. Millennium Pharmaceuticals, Inc. Velcade for injection (bortezomib) prescribing information. Cambridge, MA; 2003. Available from http://www.fda.gov/cder/foi/label/2003/ 021602lbl.pdf. Accessed January 10, 2005.
12. Cubist Pharmaceuticals, Inc. Cubicin for injection (daptomycin) prescribing information. Lexington, MA; 2003. Available from http://www.fda.gov/cder/foi/label/2003/21572_ cubicin_lbl.pdf. Accessed January 10, 2005.
13. Gilead Sciences, Inc., Emtriva (emtricitabine) capsules prescribing information. Foster City, CA; 2003. Available from http://www.fda.gov/cder/foi/ label/2003/21500_emtriva_lbl.pdf. Accessed January 10, 2005.
14. AstraZeneca Pharmaceuticals LP. Iressa (gefitinib) tablets prescribing information. Wilmington, DE; 2003. Available from http://www.fda.gov/cder/foi/ label/2004/21399slr003_Iressa_lbl.pdf. Accessed January 10, 2005.
15. Oscient Pharmaceuticals. Factive (gemifloxacin mesylate) prescribing information. Waltham, MA; 2004. Available from http://www.fda.gov/cder/foi/ label/2004/21158s003lbl.pdf. Accessed January 10, 2005.
16. Helsinn Healthcare S.A. Aloxi injection (palonosetron hydrochloride) prescribing information. Lugano, Switzerland', 2003. Available from http://www.fda.gov/cder/foi/label/2003/ 21372_aloxi_lbl.pdf. Accessed January 10, 2005.
17. Walter-Sack I, Klotz U. Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet 1996;31:47-64.
18. Cheymol G. Effects of obesity on pharmacokinetics: implications for drug therapy. Clin Pharmacokinet 2000;39:215-31.
19. Conney AH, Burns JJ. Factors influencing drug metabolism. Adv Pharmacol 1962;l:31-58.
20. Stoltz R, Cyong JC, Shah A, Parisi S. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J Clin Pharmacol 2004;44:520-31.
21. Dvorchik BH, Damphousse D. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol 2005;45:48-56.
22. Boullata JI. Influence of obesity on drug disposition and effect. In: Boullata JI, Armenti VA, eds. Handbook of drug-nutrient interactions. Totowa, NJ: Humana Press, 2004:101-26.
23. Mersfelder TL, Smith CL. Linezolid pharmacokinetics in an obese patient. Am J Health-Syst Pharm 2004;62:464-7.
24. Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003;8:508-13.
25. Fleisher D, Sweet BV, Parekh A. Drug absorption with food. In: Boullata JI, Armenti VA, eds. Handbook of drug-nutrient interactions. Totowa, NJ: Humana Press, 2004:129-54.
26. Food and Drug Administration. Guidance for industry: food-effect bioavailability and fed bioequivalence studies, December 2002. Available from http://www.fda.gov/cder/guidarice/5194fnl.pdf. Accessed October 3, 2005.
27. West SG. Effect of diet on vascular reactivity: an emerging marker for vascular risk. Curr Atheroscler Rep 2001 ;3:446-55.
28. Patel L, Lindley C. Aprepitant - a novel NKI-receptor antagonist. Expert Opin Pharmacother 2003;4:2279-96.
29. Nelson M, Schiavone M. Emtricitabine (FTC) for the treatment of HIV infection. Int J Clin Pract 2004;58:504-10.
30. Bang LM, Scott LJ. Emtricitabine: an antiretroviral agent for HIV infection. Drugs 2003;63:2413-24.
31. Blackledge G, Averbuch S. Gefitinib ('Iressa,' ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer 2004;90:566-72.
32. Swaisland H, Laight A, Stafford L, et al. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clin Pharmacokinet 2001;40:297-306.
33. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002;20: 2240-50.
34. Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002;20:3815-25.
35. Liu CY, Seen S. Gefitinib therapy for advanced non-small-cell lung cancer. Ann Pharmacother 2003;37:1644-53.
36. Cerosimo RJ. Gefitinib: a new antineoplastic for advanced non-small-cell lung cancer. Am J Health-Syst Pharm 2004;61: 889-98.
37. Swaisland H, Smith RP, Farebrother J, Laight A. The effect of the induction and inhibition of CYP3A4 on the pharmacokinetics of single oral doses of ZD1939 ('Iressa'), a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in healthy male volunteers [abstr]. Pro Am Soc Clin Oncol 2002;21:83.
38. Lode H. Evidence of different profiles of side effects and drug-drug interactions among the quinolones-the pharmacokinetic standpoint. Chemother 2001;47(suppl 3):24-31.
39. Aminimanizani A, Beringer P, Jelliffe R. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin Pharmacokinet 2001;40:169-87.
40. Zhanel GG, Noreddin AM. Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. Curr Opin Pharmacol 2001;l:459-63.
41. Allen A, Bygate E, Clark D, Lewis A, Pay V. The effect of food on the bioavailability of oral gemifloxacin in healthy volunteers. Int J Antimicrob Agents 2000;16:45-50.
42. Healy DP, Brodbeck MC, Clendening CE. Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. Antimicrob Agents Chemother 1996;40:6-10.
43. de Marie S, Vanden Bergh MFQ, Buijk SL, et al. Bioavailability of Ciprofloxacin after multiple enteral and intravenous doses in ICU patients with severe gram-negative intra-abdominal infections, Intens Care Med 1998;24:343-6.
44. Boullata JI. Natural health product interactions with medication. Nutr Clin Pract 2005;20:33-51.
45. Majumdar AK, McCrea JB, Panebianco DL, et al. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther 2003;74:150-6.
46. McCrea JB, Majumdar AK, Goldberg MR, et al. Effects of the neurokinin-1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 2003;74:17-24.
47. Shadle CR, Lee Y, Majumdar AK, et al. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 2004;44:215-23.
48. Dando TM, Perry CM. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2004;64:777-94.
49. Ranga K, Krishnan R. Clinical experience with substance P receptor (NK1) antagonists in depression. J Clin Psych 2002;63(suppl 11):25-9.
50. Stanford BL, Zondor SD. Bortezomib treatment for multiple myeloma. Ann Pharmacother 2003;37:1825-30.
51. Fenton C, Keating GM, Curran MP. Daptomycin. Drugs 2004;64:445-55.
52. Pletz MW, Petzold P, Allen A, Burkhardt O, Lode H. Effect of calcium carbonate on bioavailability of orally administered gemifloxacin. Antimicrob Agents Chemother 2003;47:2158-60.
53. Allen A, Vousden M, Porter A, Lewis A. Effect of Maalox on the bioavailability of oral gemifloxacin in healthy volunteers. Chemother 1999;45:504-11.
54. Allen A, Bygate E, Faessel H, Isaac L, Lewis A. The effect of ferrous sulphate and sucralfate on the bioavailability of oral gemifloxacin in healthy volunteers. Int J Antimicrob Agents 2000;15:283-9.
55. Boullata JI. Influence of medication on nutritional status. In: Bendich A, Deckelbaum RJ, eds. Preventive nutrition, 3rd ed. Totowa, NJ: Humana Press, 2005:833-68.
56. Said HM, Redha R, Nylander W. Biotin transport in the human intestine: inhibition by anticonvulsant drugs. Am J Clin Nutr 1989;49:127-31.
57. Mock DM, Dyken ME. Biotin catabolism is accelerated in adults receiving long-term therapy with anticonvulsants. Neurology 1997;49:1444-7.
58. Rathman SC, Eisenschenk S, McMahon RJ. The abundance and function of biotin-dependent enzymes are reduced in rats chronically administered carbamazepine. J Nutr 2002;132: 3405-10.
59. Campos D, Pereira JR, Reinhardt RR, et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001;19:1759-67.
60. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the aprepitant protocol 052 study group. J Clin Oncol 2003;21:4112-19.
61. de Wit R, Herrstedt J, Rapoport B, et al. The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomized, placebo-controlled phase III clinical trials. Eur J Cancer 2004;40:403-10.
62. Richardson PG, Hideshima T, Anderson KC. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 2003;10:361-9.
63. Davis NB, Taber DA, Ansari RH, et al. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol 2004;22:115-19.
64. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS-341 in advanced solid tumor malignancies. Clin Cancer Res 2002;8:2505-11.
65. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-7.
66. Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004:22:2108-21.
67. Campanaro ES, Talley FP, Eisenstein BI, et al. Comparison of efficacy and safety of daptomycin versus semi-synthetic penicillin and vancomycin in patients with complicated skin and skin structure infections [abstr]. In: Program and abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2003:L-737.
68. Knapp AG, Talley FP, Arbeit RD. Skeletal muscle effects in patients receiving once-daily daptomycin for complicated skin and skin structure infections [abstr]. In: Program and abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2003:L-736.
69. Veligandla SR, Louie KR, Malesker MA, Smith PW. Muscle pain associated with daptomycin. Ann Pharmacother 2004;38:1860-2.
70. Molina JM, Ferchal F, Rancinan C, et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis 2000;182:599-602.
71. Fukuoka M, Yano S, Giaccone G, et al. A multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial). J Clin Oncol 2003:21:2237-46.
72. Janne PA, Gurubhagavatula S, Yeap BY, et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer 2004;44:221-30.
73. Baselga J, Rischin D, Ranson M, et al. Phase 1 safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002;20:4292-302.
74. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA 2003;290:2149-58.
75. Simon GR, Ruckdeschel JC, Williams C, et al. Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution. Cancer Control 2003;10:388-95.
76. Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004;22:133-42.
77. Van Doorn R, Kirtschig G, Scheffer E, Stoof TJ, Giaccone G. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002;147:598-601.
78. Cohen MH, Williams GA, Sridhara R, et al. FDA drug approval summary: gefitinib (ZD1839) (Iressa®) tablets. Oncologist 2003;8:303-6.
79. Uejima H, Nakagawa K, Fukuoka M, et al. A phase 1 intermittent dose-escalation trial of ZD1839 (Iressa) in Japanese patients with solid tumors. Ann Oncol 2000;11(suppl 4) :110-11.
80. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980-7.
81. Dancey JE, Freidlin B. Targeting epidermal growth factor receptor-are we missing the mark? Lancet 2003;362:62-4.
82. Pan M, Souba WW, Karinch AM, Lin CM, Stevens BR. Epidermal growth factor regulation of system L alanine transport in undifferentiated and differentiated Caco-2 cells. J Gastrointest Surg 2002;6:410-17.
83. Kumasaka R, Nakamura N, Shirato K, et al. Side effects of therapy: nephrotic syndrome associated with gefitinib therapy. J Clin Oncol 2004;22:2504-5.
84. Lode H, File TM, Mandell L, et al. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin Ther 2002;24:1915-36.
85. Saravolatz LD, Leggett J. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. Clin Infect Dis 2003;37:1210-15.
86. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III single-dose trial versus dolasetron. Cancer 2003;98:2473-82.
87. Gralla R, Lichinitser M, Van der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570-7.
88. Siddiqui MA, Scott LJ. Palonosetron. Drugs 2004;64:1125-32.
89. Wolinsky I, Williams L, eds. Nutrition in pharmacy practice. Washington, DC: American Pharmaceutical Association, 2002.